deltatrials
Completed PHASE1/PHASE2 NCT01896856

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients

Sponsor: Astex Pharmaceuticals, Inc.

Updated 12 times since 2017 Last updated: Sep 14, 2020 Started: Oct 23, 2013 Primary completion: Aug 26, 2019 Completion: Aug 26, 2019

A PHASE1/PHASE2 clinical study on Previously Treated Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by Astex Pharmaceuticals, Inc. and has accumulated 12 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

12 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Oct 2020 — Nov 2020 [monthly]

    Completed PHASE1_PHASE2

    Phase: PHASE2PHASE1_PHASE2

Show 7 earlier versions
  1. Feb 2020 — Oct 2020 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  2. May 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  3. Oct 2018 — May 2019 [monthly]

    Recruiting PHASE2

  4. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  5. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Phase: PHASE1_PHASE2PHASE2

  6. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Astex Pharmaceuticals, Inc.
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Van Andel Research Institute
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • Amsterdam, Netherlands
  • Baltimore, United States
  • Los Angeles, United States
  • New York, United States